Replacement of cyclophosphamide/cytarabine/mercaptopurine with
cyclophosphamide /etoposide during Consolidation/Delayed
Intensification does not improve outcome for pediatric B-ALL: a report
from the COG

Michael J. Burke, Wanda L. Salzer, Meenakshi Devidas, Yunfeng Dai,
Lia Gore, Joanne M. Hilden, Eric Larsen, Karen R. Rabin, Patrick A.
Zweidler-McKay, Michael J. Borowitz, Brent Wood, Nyla A. Heerema,
Andrew J. Carroll, Naomi Winick, William L. Carroll, Elizabeth A Raetz,
Mignon L. Loh, and Stephen P. Hunger

Disclosures: M.J.B has received honoraria from Shire Pharmaceuticals, Jazz
Pharmaceuticals and Amgen. S.P.H. has received honoraria from Jazz Pharmaceuticals
and Erytech, and consulting fees from Novartis. K.R.R has received consulting fees from
Adaptive Biotechnologies. L.G. has received consulting fees from Amgen, Bristol-Myers
Squibb, Celgene, Novartis and Genentech/Roche.

S.H. designed the study; M.J.B. and W.L.S. chaired the clinical trial, analyzed the data and
wrote the manuscript; M.D. and Y.D. analyzed the data, generated the tables and figures,
reviewed and edited the manuscript; L.G., J.H., K.R.R., P.Z.M., M.B., B.W., N.H., A.C.,
E.L., N.W., W.C., M.L., E.R., and S.H. analyzed the data, reviewed and edited the
manuscript.